Piramal Pharma Ltd (NSE:PPLPHARMA)

Q2 2026 Piramal Pharma Ltd Earnings Call Transcript

Nov 6, 2025 / 08:30 PM GMT

Release Date Price: ₹199.33 (-0.54%)

Transcript

Key Points

Positve

Piramal Pharma Ltd (BOM:543635) successfully maintained a best-in-class quality and compliance track record with 0 OAIs and closed 19 inspections, including a US FDA inspection, without any observations.
The company reported a reduction in net debt by INR 228 crores over March 2025, maintaining it at less than 3 times EBITDA.
Piramal Pharma Ltd (BOM:543635) saw a significant uptick in biopharma funding in September and October, indicating early signs of recovery.
The consumer healthcare business delivered sustained growth of 15% during the quarter, driven by robust growth in power brands.
E-commerce sales grew over 40%, contributing about 24% to PCH sales, with Quick commerce accounting for over 40% of the e-commerce channel.

Negative

The company experienced a year-over-year decline in revenue due to inventory destocking by a customer in a large CDO order.
EBITDA margin moderated to 11% and 10% for the quarter and half-year, respectively, due to revenue shortfall.
There was a slower than expected pickup in early-stage discovery and development orders due to inconsistent recovery in US biopharma funding.
Sales of intrathecal therapy were subdued due to temporary supply challenges, expected to normalize in H2FY26.
The company moderated its full-year guidance to remain flat, with expectations for EBITDA margins to moderate to low 10s for the year.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

PIRM.NS - Piramal Pharma Ltd
Q2 2026 Piramal Pharma Ltd Earnings Call
Nov 06, 2025 / 08:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Ladies and gentlemen, good day and welcome to the Pyramal Pharma Limited Q2 FY26 earnings call. As a reminder, all participant clients will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes.

Should you need assistance during the conference call, please signal an operator by pressing, then 0 on your touchstone phone.

Please note that this conference is being recorded. I now hand the conference over to Mr. Gainpurana from Piramal Pharma Limited.

Thank you and over to you, sir.

--------------------------------------------------------------------------------
Unidentified_2 [2]
---------------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.